Bitget Heads to Milan as Sponsor at ETHMilan 2025
This event follows hot on the heels of Bitget's high-profile MotoGP partnership, marking a powerful back-to-back showcase of the brand's expanding influence—on the track and on the blockchain stage. ETHMilan's timing couldn't be better, as it underscores Bitget's commitment to blending mainstream visibility with meaningful industry engagement.
ETHMilan 2025 gathered more than 1,000 participants and featured over 50 speakers, including notable names like Alessandro Mazza, Marco Monaco from TAC, Stefano Rossi from PwC Italia, and Filippo Moraschi (FolksFinance). As one of Italy's largest Web3 conferences, ETHMilan has staged impactful panels on DeFi, DAOs, Ethereum scaling, and creative tech innovation.
As part of this year's program, Bitget's Chief Operating Officer, Vugar Usi Zade, took to the stage to discuss how centralized exchanges (CEXs), blockchain, and crypto infrastructure are redefining the global financial system. In a cycle where institutions and regulations are finally catching up with the technology, Vugar shared insights on how CEXs are adapting, shifting from transactional platforms to ecosystem enablers.
The appearance aligns with Bitget's broader push to shape the discourse around crypto maturity, user trust, and long-term utility. 'ETHMilan is more than a developer event—it's a signal that Milan is becoming a serious node on the global Web3 map,' said Vugar. 'Bitget is here not just to participate, but to help drive the conversations that move the industry forward.'
Bitget also hosted a breakfast reception at the Museum of Science & Technology, offering builders and industry leaders a space to connect over key themes like compliance, CeFi/DeFi evolution, and everything else crypto-related.
The event marks another milestone in Bitget's expansion across Europe, where it continues to operate under increasing regulatory clarity, including licenses in Italy, Lithuania, Georgia, and several other markets. With over 120 million users globally and a daily trading volume of $20 billion, Bitget's presence at ETHMilan reflects its commitment to driving adoption.
About Bitget
Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. Bitget is at the forefront of driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.
For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet
For media inquiries, please contact: media@bitget.com
Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
Photos accompanying this announcement are available at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
UBS Group Touches 52-Week High: Should You Buy the Stock Now?
UBS Group AG UBS shares touched a new 52-week high of $39.71 during last Friday's trading session. However, the stock closed the session a little lower at $39.54. Over the past three months, UBS shares have gained 21.7% outperforming the industry's 12.3%. Further, while it fared better than its close peer, Barclays PLC BCS, it underperformed Deutsche Bank AG DB. Three Months' Price Performance What Drove UBS Stock to Hit a 52-Week High? The recent rally partly reflects investor attention on UBS's robust second-quarter 2025 performance. The net profit attributable to shareholders surged to $2.39 billion from $1.14 billion a year earlier, driven by gains in Global Wealth Management, Asset Management, and Investment Bank units. Further, its revenues increased 1.7% year over year to $12.11 billion. Additionally, UBS's operating expenses fell 5.6% to $9.75 billion in comparison to the previous-year quarter. As a result, the company was able to achieve 70% of its targeted $13 billion in gross cost savings from the Credit Suisse merger. This highlights strong progress on integration goals. Other Factors Fueling UBS Momentum Strategic Expansion and Partnerships: UBS Group has expanded its global presence and improved its operations through strategic partnerships and acquisitions. In April 2025, UBS partnered with 360 ONE WAM Ltd, India's leading wealth and asset manager. Per the transaction, the company purchased warrants to acquire a 4.95% share and sell its Indian wealth business to 360 ONE, while continuing to serve Singapore clients from UBS Singapore. In June 2023, UBS completed the acquisition of Credit Suisse through a regulatory-assisted deal, which is expected to enhance its wealth and asset management capabilities and strengthen its capital-light businesses. Following this, UBS Switzerland AG assumed all rights and obligations of Credit Suisse (Schweiz) AG. In May 2024, UBS AG merged with Credit Suisse AG, integrating clients and operations based on business needs. By July 2024, UBS merged UBS Switzerland AG with Credit Suisse (Schweiz) AG and integrated 95 branches in Switzerland by early 2025. The company plans to migrate more Swiss clients to its system in the upcoming quarter. In the fourth quarter of 2024, UBS transferred Global Wealth Management client accounts from Luxembourg, Hong Kong, Singapore, and Japan to its platforms, moving more than 90% of accounts outside Switzerland. The main phase of Swiss client migrations is executed by the company during the second quarter of 2025 and aims to complete the Swiss booking center migrations by the end of the first quarter of 2026. These moves are expected to strengthen UBS's presence in key markets and support long-term growth. Credit Suisse Integration and Cost Synergies: UBS is successfully integrating Credit Suisse and is on track to achieve cost savings. The company plans to reduce its Non-Core and Legacy portfolio, aiming to free up over $6 billion in capital by the end of 2026. It has already cut risk-weighted assets in this division by 62%, surpassing initial goals. UBS now targets reducing these assets to below $8 billion by the end of 2025 and around $1.6 billion by the end of 2026. The firm is well-positioned to improve client experiences and lower costs further by 2026, targeting $13 billion in gross cost savings. Since late 2022, UBS has saved $9.1 billion, achieving about 70% of its goal. Solid Capital Position: UBS maintains a robust capital position, providing flexibility for strategic initiatives. As of June 30, 2025, its CET1 capital ratio stood at 14.4%, above management guidance of around 14%. The CET1 leverage ratio remained stable at 4.4%, also exceeding the target of more than 4%. UBS aims to achieve an underlying return on CET1 capital of approximately 15% by 2026-end and 18% by 2028-end. Thus, strong CET1 ratios and capital release plans underpin UBS's ability to navigate macro uncertainty and pursue growth. Solid Revenue Growth: UBS has delivered consistent top-line expansion, with overall revenues registering a three-year (2021–2024) CAGR of 11%. Within this, net interest income (NII) grew at a 4.9% CAGR and fee income at an 8% CAGR. This momentum carried into the first half of 2025, supported by robust performances across Wealth Management, Asset Management, and the Investment Bank. NII remained elevated, driven by repricing initiatives and improving loan demand, while fee income benefited from increased advisory and asset management activity. These dynamics reflect UBS's balanced revenue mix and are expected to continue fueling growth in the coming quarters. The consensus mark for UBS's 2025 sales suggests a year-over-year decline of 1.57%, followed by a year-over-year growth of 2.49% in 2026. Sales Estimates Image Source: Zacks Investment Research Earnings Strength: Over the next three to five years, the company's earnings per share (EPS) are expected to witness a growth of 47.7% outperforming the industry's growth of 11%. Additionally, UBS surpassed estimates in each of the trailing four quarters, with an average earnings surprise of 51.9%. The consensus estimate for earnings indicates a 46.7% and 39.3% rise for 2025 and 2026, respectively. Over the past month, the Zacks Consensus Estimate for earnings for 2025 and 2026 has been revised upward. Estimate Revision Trend Near-Term Concerns for UBS Elevated Expenses: UBS's rising expense base remains a key operational challenge. Operating expenses have registered 14.3% CAGR over the past four years, driven by integration costs and technology investments. Expenses declined in the first half of 2025, though continued investments in digital infrastructure and integration costs are expected to keep the expense base elevated in the near term, potentially hindering bottom-line growth. Concerning Capital Distribution Activities: The company faces concerns over its capital distribution strategy. In April 2025, it raised its dividend by 26% to 90 cents per share and aims for further increases in 2026. In April 2024, the company announced a two-year plan to buy back up to $4 billion in common stock. It completed its planned repurchase of up to $1 billion in the first half of 2025, including $0.5 billion in the second quarter. In June 2025, it approved a new two-year repurchase program to buy back up to an additional $2 billion of shares in the second half of 2025. These efforts are contingent on maintaining a CET1 capital ratio of around 14% and achieving financial targets. However, UBS's uneven quarterly performance and elevated debt-to-equity ratio of 3.77, well above the industry average of 0.87, raise questions about the sustainability of its capital distributions. Meanwhile, the debt-to-equity ratios of Deutsche Bank and Barclays are 1.39 and 5.70, respectively. UBS's Valuation Analysis In terms of valuation, UBS stock appears expensive relative to the industry. The company is currently trading at a 12-month trailing price-to-earnings P/E ratio of 14.3X, higher than the industry's 10.17X. Meanwhile, Deutsche Bank holds a P/E ratio of 9.5X, while Barclays Plc's P/E ratio stands at 7.8X. Price-to-Earnings F12 M Does UBS Stock Deserve a Place in Your Portfolio? UBS faces challenges such as rising expenses and concerns about the sustainability of its capital distribution amid uneven quarterly performance and a relatively high debt-to-equity ratio. The company's valuation also appears stretched compared to industry peers, which may concern some investors. However, UBS's solid capital position, successful integration of Credit Suisse, and consistent growth in net interest income provide a strong foundation for future growth. Its strategic partnerships, ongoing digital transformation, and disciplined cost-saving efforts further enhance its competitive advantage. With stable earnings estimates and a clear path toward efficient gains, UBS is well positioned to deliver long-term shareholder value. Currently, UBS sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Barclays PLC (BCS): Free Stock Analysis Report UBS Group AG (UBS): Free Stock Analysis Report
Globe and Mail
21 hours ago
- Globe and Mail
Imagen Network (IMAGE) Enhances Peer Discovery with Grok-Driven Personalization Engines
AI capabilities reshape social connectivity through tailored interaction models. London, United Kingdom--(Newsfile Corp. - August 11, 2025) - Imagen Network (IMAGE) has deployed advanced personalization engines powered by Grok intelligence, enabling more precise and meaningful peer discovery in decentralized social ecosystems. This integration marks a significant milestone in the project's mission to foster richer, more adaptive online interactions. Advancing AI-powered solutions for decentralized social connectivity. To view an enhanced version of this graphic, please visit: By leveraging Grok's robust inference capabilities, Imagen Network can process complex behavioral and contextual data in real time, enabling communities to connect with higher relevance and shared interests. The enhancement ensures that users experience curated engagement, reducing noise while amplifying authentic connections. This latest upgrade aligns with Imagen Network's broader vision to redefine decentralized social networking by blending AI sophistication with the transparency and autonomy of Web3. Through seamless integration of AI-powered personalization, the platform is paving the way for a new era of user-driven content discovery and collaboration. About Imagen Network Imagen Network is a decentralized social platform utilizing AI technology to provide dynamic, personalized, and transparent interactions. Its mission is to empower users with full control over their data, foster meaningful connections, and drive innovation in social engagement.
Globe and Mail
3 days ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
